Apogee Therapeutics (APGE) Jefferies Global Healthcare Conference summary

Strategic pipeline and clinical development

• Advancing fully optimized antibodies for atopic dermatitis, COPD, and asthma, with lead candidate Phase II data expected next year targeting a $50B market.

• Pursuing both monotherapy and combination approaches to maximize efficacy, aiming for first- and best-in-class status.

• OX40L and IL-13 combination is prioritized for atopic dermatitis and respiratory indications, targeting broad inflammatory pathways.

• New target added to the pipeline this year, with more details to be shared at the upcoming R&D Day.

• Safety is a primary consideration in target selection, especially for atopic dermatitis and respiratory diseases.

Scientific rationale and competitive landscape

• OX40L offers potential for broader efficacy in asthma and COPD by targeting Type I, II, and III inflammation, addressing patient populations not covered by current biologics.

• Combination of OX40L and IL-13 aims to achieve JAK inhibitor-like efficacy with a better safety profile.

• Competitors are pursuing various combinations, but many lack the breadth of inflammatory coverage or have less compelling clinical data.

• IP protection extends into the 2035-2040 range, with competitors potentially able to design around but facing strategic and partnership hurdles.

• Regulatory and reimbursement considerations, such as the IRA, influence indication selection and commercial strategy.

Clinical trial design and operational strategy

• Integrated Phase IIa/IIb trials are planned, with 110 patients in IIa and 360 in IIb, aiming to accelerate timelines and reduce costs.

• Per patient trial costs range from $150,000 to $250,000, with discipline in capital deployment and prioritization of lead programs.

• Site and country selection focuses on data quality and population homogeneity, with trials concentrated in the US, Canada, and Europe.

• Seasonality and cytokine variability are considered in trial design to ensure robust and interpretable results.

• Healthy volunteer and preclinical data are required to support combination studies, with a focus on demonstrating safety and rationale for synergy.